Royalty Report: Drugs, Cancer, Therapeutic – Collection: 169272

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 169272

License Grant
In this agreement where Licensee is the principal stockholder of Licensor, Licensor shall grant to Licensee a worldwide sublicense to practice under the Patent Rights , and to make, have made, use, lease and/or sell the Licensed Products in the Licensee Field and to practice the Licensed Processes in the Licensee Field, said sublicense to include the right to subsublicense in the Licensee Field and to be exclusive to Licensee in the Licensee Field.
License Property
These Patent Rights are licensed to the Licensor pursuant to the terms of a License Agreement dated as of October 31, 1992.

Licensee at its own expense and utilizing patent counsel of its choice shall have the sole right and responsibility for the prosecution and maintenance of the Nudelman Patent, provided that Licensee shall not take any action with respect to the Nudelman Patent that could result in any diminution of rights relating to the composition of matter claims relating to AN10.  Licensor shall have the sole right and responsibility for the prosecution and  maintenance of the Hemoglobinopathies Patent.

Hemoglobinopathies Patent shall mean issued U.S. Patent No. 5,569,675 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.

Nudelman Patent shall mean issued U.S. Patent No. 5,200,553 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.

AN 10 shall mean butylidene dibutyrate.

Field of Use
This agreement pertains to the drug industry relating to the field (a) with respect to all compounds except AN  10, all indications except (i) those covered by the Hemoglobinopathies Patent and (ii) topical applications (other than oncologic disorders) and (b) with respect to AN 10, non-topical applications for oncologic disorders.

IPSCIO Record ID: 286016

License Grant
Licensor of Israel hereby grants to Licensee a worldwide license to practice under the Patent Rights, and to make, have made, use, lease, and/or sell the Licensed Products in the Licensee Field and to practice the Licensed Processes in the Licensee Field, said license being perpetual unless sooner terminated as hereinafter provided and subject to the payment of royalties as hereinafter provided,  and said license to include the right to sublicense in the Licensee Field and to be exclusive to Licensee in the Licensee Field.
License Property
Patent Rights shall mean Israeli Patent Applications Nos. 83389 and 87072, filed July 30, 1987 and July 11, 1988, respectively; and any applications claiming priority or benefit directly or indirectly from either or both of them, including any continuations, continuations-in-part, and divisionals thereof; and any patents issuing from any of the foregoing, including any reissues, reexaminations, and extensions thereof; as set forth.

US Patent #5,200,553 – Biologically active carboxylic acid esters

Licensed Product(s) shall mean: Any product which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the product is made, used, leased, or sold; Any product which is manufactured by using a process which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the process is used; Any product which is used according to a method which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the method is used.

Licensed Process(es) shall mean any process or method, which is covered, in whole or in part, by a valid and unexpired claim contained in the Patent Rights in the country in which the process or method is used.

Field of Use
Licensee Field shall mean: (a) with respect to butylidene dibutyrate (sometimes referred to as AN-10), non-topical applications for oncologic disorders; and (b) with respect to all other products within the Patent Rights, all indications and routes of administration except (i) the treatment of (-hemoglobinopathies ((-globin disorders) and (ii) topical applications other than oncologic disorders. The term oncologic disorders shall not include chemotherapy-or radiotherapy-induced alopecia.

IPSCIO Record ID: 283199

License Grant
Licensor and its Affiliates hereby grant to Licensee an exclusive, worldwide royalty-bearing license, with the right to grant sublicenses, under any Licensor Patent Rights and to use any Licensor Know-How to make, have made, use and sell Licensed Products containing Acolbifene in the Field in the Territory (including Canada). The foregoing licenses shall be exclusive even as to Licensor. Licensor shall remain solely responsible (at its own expense) for the filing, prosecution, maintenance, enforcement and defense of the Licensor Patent Rights covering Licensed Products containing Acolbifene in the Territory which activities shall be governed by the terms of the Agreement.  This become effective as of the date on which Licensor’s licenses to Acolbifene are terminated pursuant to this agreement.

The Parties have been collaborating in the development of a certain antiestrogen compound as a Licensed Compound under the terms of the Agreement.

Licensee now desires to assume sole responsibility for the continued development of such antiestrogen compound.

License Property
Acolbifene shall mean the specific antiestrogen compound known as acolbifene (also referred to by the parties as EM-652 or SCH 57068) and having the chemical structure.

Licensed products means any pharmaceutical products in dosage form which contain one or more Licensed Compounds, including without limitation, Licensed Combinations.

Licensed Compounds means (i) any compounds existing on the effective date of this Agreement which were conceived of as antiestrogen or antiandrogen compounds by or on behalf of Licensee and (ii) any additional novel or existing compounds which are conceived of as compounds in the Field by or on behalf of Licensee while carrying out research in the program as that term is defined.

Patent Rights means (i) all pending United States patent applications and issued patents relating to Licensed Compounds, including without limitation, the pending United States patent applications and issued patents listed, as of the effective date of this Agreement; (ii) all claims of any patent applications or issued patents filed or issued during or after the term of this Agreement to which Licensee have rights covering any compositions for, processes for or methods of use of any Licensed Compounds in the Field; (iii) all claims of any foreign counterpart patent applications and/or issued patents of (i) and (ii) and (iv) any reissues, extensions, substitutions, confirmations, registrations, revalidations, additions, continuations, continuations-in-part or divisions of or to any of the foregoing which are hereafter granted in the Territory.

Field of Use
Acolbifene is a nonsteroidal selective estrogen receptor modulator which, as of 2015, is in phase III clinical trials for the treatment of breast cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.